Quick Answer
Entrada Therapeutics, Inc. reported Stockholders Equity of $306.13 million for fiscal year 2025.
Entrada Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $306.13M | -28.6% |
| 2024 | $428.68M | +76.9% |
| 2023 | $242.36M | +14.0% |
| 2022 | $212.55M | -28.8% |
| 2021 | $298.72M | +820.0% |
| 2020 | -$41.49M | -167.4% |
| 2019 | -$15.52M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $340.72M | -19.3% | -10.2% |
| June 30, 2025 | $379.50M | -11.7% | -9.0% |
| March 31, 2025 | $417.26M | +54.9% | -2.7% |
| December 31, 2024 | $428.68M | +76.9% | +1.5% |
| September 30, 2024 | $422.45M | +71.3% | -1.7% |
| June 30, 2024 | $429.93M | +107.8% | +59.6% |
| March 31, 2024 | $269.37M | +17.3% | +11.1% |
| December 31, 2023 | $242.36M | +14.0% | -1.7% |
- Entrada Therapeutics, Inc. showed a decrease of -28.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Entrada Therapeutics, Inc.’s stockholders equity has grown by 2072.8% (from -$15.52 million to $306.13 million).
- The most recent figure is from Entrada Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: